Morphine, Dyspnea, Exercise and COPD

• Status: Unknown status
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators are studying the effect of a single dose Opioid drug (Morphine) on dyspnea and exercise tolerance in COPD patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McGill University Health Center; McGill University Health Centre/Research Institute of the McGill University Health Centre
• Treatments: Morphine

Criteria

Inclusion Criteria:

• sever or very sever COPD, i.e. post B2 agonist FEV1<50% predicted

• age >= 40 years

• cigarette smoking history > 2 pack yrs

• ever chronic activity-related dyspnea defined by the combination of A BDI focal score <=6, Modified MRC dyspnea scale >=3 and an OCD rating <=50

• no change in medication dosage & frequency in the preceding 6 weeks

• no hospitalization or exacerbation in the preceding 6 weeks

Exclusion Criteria:

• active cardiopulmonary disease other than COPD

• contraindication to Cardiopulmonary exercise testing

• use of daytime oxygen

• exercise-induced oxyhemoglobin desaturation to <80% on room air

• Body mass index <18.5 or >30 kg/m2

• use of antidepressant drugs in the preceding 2 weeks

• use of opioid drugs in the preceding 4 weeks

• partial pressure of carbon dioxide PCo2 of >50 mmHg on capillary blood gas